Treatment of Lower Respiratory Tract Infections with Amoxycillin/Clavulanic Acid in Adults
| Autor: | M Veslemes, A. Votsiou, G Tatsis, C Hadjistavrou, J Jordanoglou |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Chronic bronchitis medicine.medical_specialty Administration Oral 030204 cardiovascular system & hematology Biochemistry Gastroenterology Sputum culture Clavulanic Acids 03 medical and health sciences 0302 clinical medicine Internal medicine Clavulanic acid Lower respiratory tract infection Humans Medicine Bronchitis Clavulanic Acid Aged Aged 80 and over Emphysema Bronchiectasis medicine.diagnostic_test Respiratory tract infections business.industry Biochemistry (medical) Amoxicillin Pneumonia Cell Biology General Medicine Middle Aged medicine.disease Anti-Bacterial Agents Surgery Drug Combinations 030220 oncology & carcinogenesis Injections Intravenous Sputum Female medicine.symptom business medicine.drug |
| Zdroj: | Journal of International Medical Research. 21:98-101 |
| ISSN: | 1473-2300 0300-0605 |
| DOI: | 10.1177/030006059302100205 |
| Popis: | Patients with lower respiratory tract infections [pneumonia ( n = 16), bronchiectasis ( n = 5) and acute exacerbations of chronic bronchitis ( n = 44)] were treated daily with amoxycillin/clavulanic acid given either 1.2 g intravenously three times daily or 625 mg orally three times daily for 7–15 days. Symptoms, signs and sputum volume and colour were monitored daily. Chest X-ray, sputum culture and Gram-stain examinations were also carried out on days 1 and 5, and immediately after the end of the treatment. There was a clinical improvement, as indicated by the incidence of cough, dyspnoea and rales, and by sputum volume and colour in 90.8% of the patients. Microbiological improvement, as indicated by the complete elimination of sputum pathogens and pus cells, was achieved in the same proportion of patients (90.8%). In one patient, an adverse side-effect, diffuse exanthema, was noted. Amoxycillin/clavulanic acid possesses a high clinical and microbiological efficacy for lower respiratory tract infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|